Clinical Trial: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naive Higher-risk Myelodysplastic Syndromes

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07672769) titled 'Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naive Higher-risk Myelodysplastic Syndromes' on April 27.

Brief Summary: This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naive higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended do...